MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2019 International Congress

    Evaluating the Inappropriate Use of Antipsychotics in Parkinson’s Disease Psychosis Patients Within Large National US Healthcare Databases

    A. Shim, V. Abler, N. Rashid (San Diego, CA, USA)

    Objective: To identify Parkinson’s disease psychosis (PDP) treatment characteristics from an aggregate of US national insurer and Medicare databases. Background: Treatment of psychotic symptoms associated…
  • 2019 International Congress

    A life-threatening case of Anti-IgLON5 disease

    M. Filidei, N. Tambasco, F. Paolini Paoletti, S. Simoni, E. Brahimi, G. Cappelletti, P. Nigro, P. Calabresi (Perugia, Italy)

    Objective: To present a case of anti-IgLON5 disease with life-threatening respiratory complications. Background: Anti-IgLON5 disease is a little known CNS disorder characterized by non-REM and…
  • 2019 International Congress

    The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

    A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: We seek to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…
  • 2019 International Congress

    LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset

    A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: We aim to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…
  • 2019 International Congress

    Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment

    B. Kennedy, J. Peterson, D. Charles (Washington, DC, USA)

    Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…
  • 2018 International Congress

    In vivo MRI signatures of hippocampal subfield pathology in patients with Parkinson’s disease and psychosis

    A. Lenka, M. Ingalhalikar, A. Shah, J. Saini, S. Hegde, A. Shyam Sundar, R. Yadav, P. Pal (Bangalore, India)

    Objective: To study the role of hippocampal subfield pathology in the genesis of psychotic symptoms in patients with Parkinson's disease (PD) by comparing the volumes…
  • 2018 International Congress

    Neuropathological correlates of psychiatric disorders in PD

    J. Hinkle, N. Fischer, K. Perepezko, C. Bakker, M. Broen, A. Butala, T. Dawson, A. Leentjens, Z. Mari, C. Marvel, K. Mills, E. Moukheiber, A. Pantelyat, O. Pletniková, L. Rosenthal, M. Shepard, J. Troncoso, J. Wang, G. Pontone (Baltimore, MD, USA)

    Objective: To test the hypothesis that neuropsychiatric symptoms (NPS) in PD are associated with histopathologically confirmed neuronal loss and gliosis (NLG) in the locus coeruleus…
  • 2018 International Congress

    Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis

    A. Espay, M. Guskey, N. Larsen, B. Coate, J. Vizcarra, S. Factor, J. Friedman, D. Weintraub, A. Lang (Cincinnati, OH, USA)

    Objective: To evaluate the differential antipsychotic effect of pimavanserin, a selective serotonin (5-HT2A) receptor inverse agonist, for Parkinson’s disease psychosis with and without concomitant anti-dementia…
  • 2018 International Congress

    Suicide attempts, suicidal and death ideation in Parkinson’s disease

    MM. Dumitru, A. Papari (Iasi, Romania)

    Objective: The objective of this study was to assess the correlates of suicidal and death ideation and suicide attempts in patients with parkinson’s disease. Background:…
  • 2018 International Congress

    Patients with Parkinson’s disease and psychosis have altered structural connectivity of the executive and visual networks

    P. Pal, A. Lenka, M. Ingalhalikar, A. Shah, J. Saini, S. Arumugham, S. Hegde, L. George, R. Yadav (Bangalore, India)

    Objective: To analyze the integrity of visual and executive network of patients with Parkinson’s disease (PD) with psychosis (PD-P) and those without psychosis (PD-NP) and…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley